Trial · NCT00577590
Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
NCT00577590, Not applicable, Completed, Washington University School of Medicine; results first posted 2018-08-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM. Trials, record NCT00577590. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00577590
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
- NCT number
- NCT00577590
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 78 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Metformin, Rosiglitazone, Lovaza
- First posted
- 2007-12-20
- Last updated
- 2018-08-31
- Results first posted
- 2018-08-31
- Limitations and caveats
- There were no limitations or caveats
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change in Plasma Triglycerides | Baseline and 3 months |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Plasma Triglycerides | Baseline and 3 months | Data presented are stratified by sex | percent change | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in Plasma Triglycerides | Metformin and Lovaza | Plasma triglycerides women | -2.0 | Standard Deviation 12 | percent change |
| Percent Change in Plasma Triglycerides | Metformin | Plasma triglycerides women | 16.0 | Standard Deviation 30 | percent change |
| Percent Change in Plasma Triglycerides | Metformin and Rosiglitazone | Plasma triglycerides women | -5.0 | Standard Deviation 15 | percent change |
| Percent Change in Plasma Triglycerides | Metformin and Lovaza | Plasma triglycerides men | -5.0 | Standard Deviation 12 | percent change |
| Percent Change in Plasma Triglycerides | Metformin | Plasma triglycerides men | -10.0 | Standard Deviation 5 | percent change |
| Percent Change in Plasma Triglycerides | Metformin and Rosiglitazone | Plasma triglycerides men | 1.0 | Standard Deviation 12 | percent change |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Metformin and Lovaza | 28 | |
| Overall Study | STARTED | Metformin | 27 | |
| Overall Study | STARTED | Metformin and Rosiglitazone | 23 | |
| Overall Study | COMPLETED | Metformin and Lovaza | 28 | |
| Overall Study | COMPLETED | Metformin | 27 | |
| Overall Study | COMPLETED | Metformin and Rosiglitazone | 23 | |
| Overall Study | NOT COMPLETED | Metformin and Lovaza | 0 | |
| Overall Study | NOT COMPLETED | Metformin | 0 | |
| Overall Study | NOT COMPLETED | Metformin and Rosiglitazone | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Metformin and Lovaza | 0 | 28 |
| Total, all-cause mortality | Metformin | 0 | 27 |
| Total, all-cause mortality | Metformin and Rosiglitizone | 0 | 23 |
| Total, other adverse events | Metformin and Lovaza | 0 | 28 |
| Total, other adverse events | Metformin | 0 | 27 |
| Total, other adverse events | Metformin and Rosiglitizone | 0 | 23 |
| Total, serious adverse events | Metformin and Lovaza | 0 | 28 |
| Total, serious adverse events | Metformin | 0 | 27 |
| Total, serious adverse events | Metformin and Rosiglitizone | 0 | 23 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00577590
GET https://conductscience.org/api/trials/v1/NCT00577590/registered